Conditions: Non Small Cell Lung Cancer Lung Cancer
Keywords: NSCLC Phase II ZD4054 Pemetrexed Lung Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 66
Healthy volunteers: no

Brief summary:
The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone

Detailed description:

Arms:
arm 1: ZD4054 + Pemetrexed arm 2: ZD4054 matched placebo + pemetrexed

Interventions: intervention 1: ZD4054 intervention 2: Pemetrexed intervention 3: Placebo
Intervention descriptions: intervention 1: 10mg oral tablet, once daily intervention 2: 500mg2/m IV infusion intervention 3: 10mg oral tablet, once daily

Protocol document: